-
货号
DHD72201
-
描述
Varlilumab is a fully human monoclonal antibody (mAb) that targets CD27, a critical molecule in the activation pathway of lymphocytes. Like CD40, CD27 can be effectively manipulated with activating antibodies to induce potent anti-tumor responses, and may result in less toxicities due to its restricted expression and regulation. Varlilumab is a novel, first-in-class, agonist CD27 antibody that stimulates the CD27 pathway, which results in T-cell activation and antitumor activity in tumor models. This first-in-human, dose-escalation and expansion study evaluated the safety, pharmacology, and activity of varlilumab in patients with advanced solid tumors.
-
表达系统
Mammalian Cells -
种属反应性
Human -
宿主
Human -
同种型
IgG1-kappa -
克隆类型
Monoclonal -
靶标
CD27L receptor, TNFRSF7, T14, CD27 antigen, Tumor necrosis factor receptor superfamily member 7, CD27, T-cell activation antigen CD27 -
浓度
2 mg/ml -
内毒素水平
Please contact with the lab for this information. -
纯度
>95% as determined by SDS-PAGE. -
纯化方式
Protein A/G purified from cell culture supernatant. -
Accession号
-
克隆号
Varlilumab
-
应用
Research Grade Biosimilar -
状态
Liquid -
保存溶液
0.01M PBS, pH 7.4. -
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. -
别名
1F5, CDX-1127, CAS: 1393344-72-3
